English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduCancer immunotherapy involves using activated T cells to destroy tumors, but it doesn’t work for all patients. Researchers at Washington University School of Medicine in St. Louis have discovered that a kind of dendritic cell is crucial for determining the effectiveness of immunotherapy. The discovery could lead to new ways to extend the benefits of immunotherapy to more patients.
Tag: Melanoma
Spot the cancer: new advances in melanoma detection
New biomarkers to improve skin cancer detection and avoid delays in treatment are being developed by researchers at the University of South Australia.
Biomarker Predicts Resistance to Immunotherapies in Melanoma
Duke Cancer Institute researchers have identified potential biomarkers that predict the likelihood for checkpoint inhibitor drugs to backfire, driving hyper-progression of melanoma cells instead of unleashing the immune system to fight them.
New research shows indoor tanning can increase melanoma risk
With the holidays almost upon us, your audience may be headed to their favorite salon to keep their summer tans. However, using tanning beds is putting them at risk for developing melanoma, the deadliest form of skin cancer. A new…
MD Anderson Research Highlights: SITC 2022 Special Edition
This special edition features upcoming presentations by MD Anderson researchers at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, including immunotherapy advances in human papillomavirus (HPV)-positive head and neck cancers, microbiome signatures linked with specialized immune-cell clusters, and promising early activity from novel immunotherapy drugs in advanced melanoma and colorectal cancer.
Researchers identify a subset of patients with early melanoma who face a very low risk of dying from the disease
Although melanoma is the most serious type of skin cancer, most patients have high chances of surviving the disease. There is evidence that more cases of melanoma are being overdiagnosed in patients who would never experience symptoms.
MD Anderson Research Highlights for November 3, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts.
Reprogramming of immune cells shown to fight off melanoma
A new way of reprogramming our immune cells to shrink or kill off cancer cells has been shown to work in the otherwise hard to treat and devastating skin cancer, melanoma.
CANCER RESEARCH INSTITUTE TO HOST ANNUAL VIRTUAL IMMUNOTHERAPY PATIENT SUMMIT ON NOVEMBER 11-12, 2022
Free online event for cancer patients and caregivers featuring immunotherapy experts and patient advocates taking place Nov. 11-12, 2022.
MD Anderson Research Highlights for October 19, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include a combination approach to overcome PARP inhibitor resistance in breast and ovarian cancers, a deeper understanding of STAT3 mutations as drivers of disease progression, insights into the “obesity paradox” in men with advanced melanoma, a prognostic model for rapidly progressing vestibular schwannoma, and a role for cellular trafficking proteins in creating a metastasis-promoting lung cancer microenvironment.
Moffitt Researchers Discover Connection Between Stress-Activated Signaling and Immune Cell Evasion in Melanoma
Moffitt Cancer Center researchers wanted to determine how PERK activity impacts the clinical outcomes of patients with melanoma. Their results are published in a new article in Cancer Cell.
Advanced Melanoma Survival Improves Significantly When Immunotherapy is Given Before Targeted Therapy
A clinical trial led by clinicians at Georgetown Lombardi Comprehensive Cancer Center showed a remarkable 20 percent advantage in the two-year overall survival rate for people with advanced melanoma who first received immunotherapy (72 percent survival rate) versus those who initially got targeted therapies (52 percent survival rate). Progression-free survival, where the cancer is stable or improving, was also trending in favor of those who started on immunotherapy.
Wistar Scientists Identify Key Biomarkers that Reliably Predict Response to Immune Checkpoint Inhibitor Therapy for Melanoma
Currently, the only FDA approved biomarker for ICI melanoma treatment is the tumor mutation burden assay, but the mechanisms linking it to ICI remain unclear. However, new research out of The Wistar Institute now provides evidence of novel, reliable biomarkers that predict therapy response using advanced computer technology.
MD Anderson Research Highlights: ESMO 2022 Special Edition
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. This special edition features upcoming oral presentations by MD Anderson researchers at the European Society for Medical Oncology (ESMO) Congress 2022 focused on clinical advances across a variety of cancer types. Highlights include promising early data from a novel T cell therapy for solid tumors, targeted therapy progress in rare and advanced cancers, biomarkers of immunotherapy response, and features associated with clinical outcomes in leptomeningeal disease. More information on ESMO content from MD Anderson can be found at MDAnderson.org/ESMO.
Moffitt Physicians Lead International Study to Identify Melanoma Patients with High-Risk Disease
In a new study published in the Journal of Clinical Oncology, Moffitt Cancer Center physicians, along with a team of international researchers from eight other cancer centers, report on their identification of high-risk patients with stage 3A disease and microscopic lymph node metastases who would benefit from adjuvant therapy.
MD Anderson Research Highlights for July 27, 2022
Clinical advances include treating hematologic cancers with effective targeted therapies, circulating tumor DNA as a biomarker for recurrence with colorectal liver metastases, and using magnetic resonance imaging (MRI) to guide surgical decisions for patients with lateral pelvic lymph node metastases in rectal cancer. Laboratory findings offer new understanding of the pancreatic cancer immune microenvironment, melanoma cell states, TP53 mutation status in acute myeloid leukemia (AML), and potential targets for metastatic prostate cancer and GNAS-mutant colorectal cancer.
Melanoma Thickness Equally Hard for Algorithms and Dermatologists to Judge
Assessing the thickness of melanoma is difficult, whether done by an experienced dermatologist or a well-trained machine-learning algorithm.
MD Anderson Research Highlights for July 13, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include new targets involved in protecting DNA replication forks and preventing inflammatory responses, a new treatment option for elderly patients with late-stage acute myeloid leukemia, insights into the breast cancer tumor microenvironment, biomarkers of response to targeted and immune therapies, a novel cellular therapy option for osteosarcoma and a new target for inducing ferroptosis in cancer cells.
New gene profiling technology reveals melanoma biomarkers
New technology used by UC Davis researchers has uncovered melanoma biomarkers expressed by specific tumor cells as well as neighboring cells in the so-called tumor microenvironment. The study results may help diagnose melanoma earlier when it is more treatable.
Plant virus plus immune cell-activating antibody clear colon cancer in mice, prevent recurrence
A new combination therapy to combat cancer could one day consist of a plant virus and an antibody that activates the immune system’s “natural killer” cells, shows a study by researchers at the University of California San Diego. In mouse models of colon cancer, the combination therapy eliminated all tumors and prevented their recurrence, which in turn resulted in 100% survival. The therapy also increased survival in mouse models of melanoma.
Androgen receptor signaling contributes to targeted therapy resistance in melanoma
Androgen receptor (AR) signaling affects response to BRAF/MEK inhibitor therapy in both males and females with melanoma, researchers from The University of Texas
Dogs inhale immunotherapy to test lung cancer treatment
An inhaled immunotherapy successfully treated cancer in some companion dogs as part of a clinical trial conducted by UC Davis oncology and veterinary researchers. Recently published study results show potential for fighting cancer in humans as well.
UCLA study identifies receptor that could alleviate need for chemo, radiation pre-T cell therapy
A research team led by UCLA’s Anusha Kalbasi, MD, has shown that a synthetic IL-9 receptor allows cancer-fighting T cells to do their work without the need for chemotherapy or radiation.
MD Anderson Research Highlights for June 1, 2022
Current advances include new biomarkers to predict chimeric antigen receptor (CAR) T cell therapy outcomes and neurotoxicities, novel treatment targets for pre-cancerous pancreatic lesions and T-cell acute lymphoblastic leukemia, a new approach to improve immunotherapy responses in cold tumors, a profile of synthetic lethal targets for cancers with tumor suppressor loss, and promising clinical data for acute myeloid leukemia and cancers of unknown primary.
Age-Related Lung Changes Provide Pathway for Metastatic Growth of Dormant Melanoma Cancer Cells
New laboratory research directed by investigators at the Johns Hopkins Kimmel Cancer Center and the Johns Hopkins Bloomberg School of Public Health finds that secreted age-induced changes in distant sites such as the lung can effectively reactivate dormant cells and cause them to grow.
MD Anderson Research Highlights: ASCO 2022 Special Edition
This special edition features upcoming oral presentations by MD Anderson researchers at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting focused on quality improvement, health services research, new treatments for skin cancers, and symptoms and survivorship advances. More information on ASCO content from MD Anderson can be found at MDAnderson.org/ASCO.
Next-Generation Immunotherapy Drug Shows Continued Promise in Several Advanced-Stage Cancers
Initial study results show that an experimental drug, called nemvaleukin alfa, when used alone or in combination with another anticancer drug (pembrolizumab) may be effective in treating several types of late-stage cancers in some patients.
Many pathologists agree overdiagnosis of skin cancer happens, but don’t change diagnosis behavior
Recent studies finding that there is an overdiagnosis of melanoma are a significant cause for concern. However, while many pathologists agree overdiagnosis of skin cancer happens, they don’t change diagnosis behavior.
How Common is Skin Cancer? And More Questions You’re Afraid to Ask
Sarah Weiss, MD, medical oncologist at Rutgers Cancer Institute of New Jersey and associate professor of medicine at Rutgers Robert Wood Johnson Medical School, answers questions about skin cancer and sun protection that you may be wondering
National Healthy Skin Month: Dermatologists encourage regular skin checks
The American Academy of Dermatology highlights the importance of regular skin self-exams during National Healthy Skin Month this November. These exams help catch serious conditions early when they are most treatable. Research shows nearly one in four Americans have skin disease. Skin cancer remains the most common cancer in the United States with an estimated 9,500 people diagnosed every day.
Combination immunotherapy improves survival for patients with asymptomatic melanoma brain metastases
Combination treatment with immune checkpoint inhibitors nivolumab and ipilimumab demonstrates overall survival for patients with melanoma that has spread to the brain, according to Phase II study results published today in The Lancet Oncology by researchers from The University of Texas MD Anderson Cancer Center.
Drugs Designed for Prostate Cancer Show Promise for Treating Melanoma in Men
PHILADELPHIA— New research shows that testosterone promotes melanoma proliferation by activating a newly recognized nonclassical testosterone receptor in melanoma cells called ZIP9 (encoded by the SLC39A9 gene), a zinc transporter that is not intentionally targeted by any available therapeutics but is widely expressed in human melanoma.
New study shows that different types of cancers are likely to spread to specific areas of the brain
Brain metastasis occurs when cancer in one part of the body spreads to the brain. The lifetime incidence of such metastatic brain tumors in cancer patients is between 20%-45%, research shows.
Wistar and Penn Medicine Awarded $11.7 Million Melanoma Research Grant from the National Cancer Institute
The Wistar Institute and Penn Medicine have been awarded a prestigious $11.7 million Specialized Programs of Research Excellence, or SPORE, grant from the National Cancer Institute.
Johns Hopkins Cancer Researcher Ashani Weeraratna Appointed To National Cancer Advisory Board By President Biden
Johns Hopkins scientist Ashani Weeraratna, PhD, a leading cancer researcher who specializes in melanoma and the effects of aging on cancer, has been appointed by President Joe Biden to serve as a member of the National Cancer Advisory Board.
How a plant virus could protect and save your lungs from metastatic cancer
Using a virus that grows in black-eyed pea plants, researchers developed a new therapy that could keep metastatic cancers from spreading to the lungs, as well as treat established tumors in the lungs.
New Insights about Melanocytes Could Lead to More Targeted Melanoma Treatments
Huntsman Cancer Institute melanoma researchers have generated the first “atlas” of human melanocytes located in the body.
UCLA researchers awarded $1M from DOD to advance CAR T cell therapy for rare melanomas
Scientists Dr. Cristina Puig-Saus and Dr. Daniel Shin from the UCLA Jonsson Comprehensive Cancer Center have received a $1 million Translational Research Award from the U.S. Department of Defense Melanoma Research Program to help advance the use of chimeric antigen receptor, or CAR, T cell therapy as a treatment for people with acral, mucosal and uveal melanomas.
Sylvester Comprehensive Cancer Center Researchers Awarded Major Multi-Center Grant to Study Uveal Melanoma
Researchers at the Sylvester Comprehensive Cancer Center in the University of Miami Miller School of Medicine, Moffitt Cancer Center and the University of Florida Health Cancer Center received a five-year, $3.95 million NIH grant to study how uveal melanoma spreads to the liver. This work was previously supported by two Florida State Team Science Awards, which provided early-stage funding to help the team progress to the larger NIH grant.
Melanoma awareness: When should you see a dermatologist?
While it is the least common of the main types of skin cancer, melanoma is the deadliest form of skin cancer. The sooner it is detected, the better.
Study reveals source of DNA mutations in melanoma
GRAND RAPIDS, Mich. (JULY 30, 2021) — The mutations that give rise to melanoma result from a chemical conversion in DNA fueled by sunlight — not just a DNA copying error as previously believed, reports a study by Van Andel Institute scientists published today in Science Advances.
New grant, National Fellowship for UA Little Rock Nanotechnology Researcher
Dr. K. Bao Vang-Dings, a nanotechnology researcher at the University of Arkansas at Little Rock, has been named one of nine 2021-22 Public Policy Fellows by the American Association of Immunologists. Additionally, the Arkansas IDeA Network of Biomedical Research Excellence (INBRE) has awarded her a 2021 Summer Research Grant to support Vang-Dings’ cancer vaccine research.
Study identifies gut microbes associated with toxicity to combined checkpoint inhibitors in melanoma patients
Researchers from The University of Texas MD Anderson Cancer Center found specific intestinal microbiota signatures correlate with high-grade adverse events and response to combined CTLA-4 and PD-1 blockade treatment.
Cell-based immunotherapy shows promise against melanoma
Researchers at Washington University School of Medicine in St. Louis have shown in preclinical studies conducted in mice and human cells that a type immunotherapy based on natural killer cells could be effective against solid tumors, starting with melanoma, a type of skin cancer that can be deadly if not caught early.
Skin Cancer & Melanoma
Skin cancer is the most common cancer in the United States. Doing a monthly at home self-check of your skin can help you spot changes. Learn how to spot lesions and skin changes from Mountainside Medical Center.
Leopard Gecko Skin Tumors Traced to Cancer Gene
In a rare gecko color variety known as Lemon Frost, scientists have traced an unusual coloring and tendency to form tumors to a gene linked to human melanoma.
Astronomy Meets Pathology to Identify Predictive Biomarkers for Cancer Immunotherapy
Pairing sky-mapping algorithms with advanced immunofluorescence imaging of cancer biopsies, researchers at The Mark Foundation Center for Advanced Genomics and Imaging at Johns Hopkins University and the Bloomberg~Kimmel Institute for Cancer Immunotherapy developed a robust platform to guide immunotherapy by predicting which cancers will respond to specific therapies targeting the immune system.
Dual Immunotherapy Regimen Delays Cancer Progression in Patients with Advanced Melanoma
A treatment regimen for patients with advanced melanoma that combines the immunotherapy agents relatlimab (anti-LAG-3) and nivolumab (anti-PD-1) delayed time to cancer progression significantly more than nivolumab alone, according to results of a study to be presented June 6 at the 2021 American Society of Clinical Oncology (ASCO) annual meeting.
Survival benefits of immunotherapy combination persist for more than six years in patients with advanced melanoma
In the longest follow-up results from a clinical trial of combination immunotherapy for metastatic melanoma, investigators report that nearly half the patients who received the drugs nivolumab and ipilimumab were alive a median of six and a half years after treatment.
Cleveland Clinic experts available to comment on cancer research presented at ASCO Annual Meeting
Cleveland Clinic cancer researchers are involved with more than 50 studies that’ll be presented at the virtual American Society of Clinical Oncology (ASCO) Annual Meeting, June 4—8, 2021. Key research from Cleveland Clinic focuses on advancements in the prevention and…